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Abstract: Cardiovascular diseases (CVDs) are one of the foremost causes of high morbidity
and mortality globally. Preventive, diagnostic, and treatment measures available for CVDs
are not very useful, which demands promising alternative methods. Nanoscience and nano-
technology open a new window in the area of CVDs with an opportunity to achieve effective
treatment, better prognosis, and less adverse effects on non-target tissues. The application of
nanoparticles and nanocarriers in the area of cardiology has gathered much attention due to
the properties such as passive and active targeting to the cardiac tissues, improved target
specificity, and sensitivity. It has reported that more than 50% of CVDs can be treated
effectively through the use of nanotechnology. The main goal of this review is to explore the
recent advancements in nanoparticle-based cardiovascular drug carriers. This review also
summarizes the difficulties associated with the conventional treatment modalities in compar-
ison to the nanomedicine for CVDs.
Keywords: cardiovascular diseases, nanoscience, nanoparticles, nanomedicine, nanocarriers,
treatment
Introduction
Cardiovascular diseases (CVDs) are one of the leading causes of death worldwide. The
World Heart Federation stated that the number of deaths occurring in a year due to
CVDs is 17.3 million.1 Diagnosis and treatment costs of CVDs were rising at a higher
rate and anticipated to escalate more in the next ten years. The high economic burden
associated with CVDs is due to the increase in the risk factors of CVDs such as
diabetics, obesity, and expansion of the geriatric population.2 Current statistics show
that cardiovascular diseases have anticipated being the single foremost cause of deaths
in the world. The number of death due to CVDs, especially by heart disease and stroke,
will exceed 23.3 million by 2030.3 A review on ‘psychosocial factors and cardiovas-
cular diseases’ investigates the effect of psychosocial factors on morbidity and mor-
tality rate of CVDs. Negative emotional states (depression, anger, anxiety, and
hostility), social ties, social support, social conflict, and chronic and acute psychosocial
stressors have connected with the increased risk of cardiovascular morbidity and
mortality. These psychosocial factors have a direct effect on pathophysiologic mechan-
isms that promote atherosclerosis and its clinical manifestations.4
Hypertension and CVDs
CVDs has characterized by destitute blood perfusion in the body.5 One of the most
common incidents in non-communicable CVDs is hypertension or high blood
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pressure. Hypertension is responsible for the high ratio of
mortality contributed by CVDs worldwide. Hypertension
has observed in all groups of people irrespective of their
age and sex. Generally, significant organs in the body such
as heart, brain, blood vessels, eyes, and kidneys have
damaged by high blood pressure. Hypertension also leads
to the occurrence of different CVDs, such as ischemia,
atherosclerosis, congestive heart failure, and cardiac arrest.
According to a report published in 2015, approximately
1.13 billion people are affected by hypertension globally.6
The only solution to reduce the incidence and mortality
rate of CVDs is to incorporate a healthy and preventive
lifestyle as well as early diagnosis of the diseases. The
initial diagnosis could save millions of lives annually and
also improve the quality of life.7 The response of patients
to the current therapeutic methods is limited and not
practical.8 It has reported that a close link exists between
diabetes mellitus and CVDs. CVDs are the most common
cause of morbidity and mortality in diabetic populations in
both man and woman populations. The mortality rate due
to CVDs is higher in adult populations with diabetes than
those without people with diabetes in the US. The higher
mortality rates observed with diabetic patients are due to
an increased risk of myocardial infarction and stroke.
Types of CVDs and Associated Risk
Factors
Atherosclerosis is an essential factor of stroke and other
CVDs. Retention of lipoproteins on the sub-endothelial
extracellular matrix induces the formation of atherosclero-
tic plaques. The interaction of lipid accumulation and the
inflammatory response results in the progression of pla-
ques. Generally, plaques have destroyed through oxidative
stress, proteases, and inflammation. Proteases directly
breakdown the collagen network and rupture the plaque.
The rupture of the plaque can lead to myocardial infarc-
tion, and stroke.9 Acute myocardial infarction and
ischemic death of cardiomyocytes are one of the most
severe types of atherosclerotic cardiovascular disease.
Coronary artery disease is another leading cause of mor-
tality globally, which can be life-threatening when it
develops into acute myocardial infarction.10 Coronary
artery diseases are caused by coronary atherosclerosis
due to the coronary artery stenosis or occlusion. It has
reported that mitochondria play an essential role in ther-
apeutic strategies to reduce the size of myocardial infarct
size and thus prevents heart failure in ischemic heart
disease patients. Mitochondrial dysfunction can lead to
acute myocardial perfusion injury followed by acute myo-
cardial infarction.11
CVDs also include heart failure, which is a complex
pathophysiological syndrome that arises due to the
impaired function of the heart to fill or eject the blood.
Different clinical manifestations have associated with
heart failure along with myocardial insults such as genetic
factors, hypertension, hypertrophy, and coronary artery
disease. The incidence of symptomatic heart failure rises
with the increasing age, and heart failure is reported as the
primary cause of more than 55,000 deaths each year.
Hypertrophied heart or myocardial hypertrophy occurs
due to the increase in the cardiomyocyte size. Usually,
adult mammalian cardiomyocytes tend to have reduced
proliferative capacity, and the size of the heart starts to
increase in response to the stress or increased workload
such as hypertension, aortic stenosis, vascular heart dis-
ease, and myocardial infarction. It leads to the develop-
ment of hypertrophied heart or myocardial hypertrophy.
Myocardial hypertrophy is followed by the augmented
synthesis of proteins, improved expression of embryonic
genes, and assembly of sarcomeres, perivascular, and
fibrosis, which eventually leads to heart failure. Another
complication associated with the heart is restenosis, which
has an incidence of 30–40% among the population.12
CVDs also include restenosis and aneurysm. Restenosis
occurs as a serious complication of vascular interventional
procedures, resulting in abnormal narrowing of the blood
vessel. It is because vascular interventional procedures tend
to focus on the restoration of blood flow across the obstructed
arteries. Angioplasty and stent implants remove the occlu-
sion and involve in the expansion of the inner diameter of the
artery with an enhanced hemodynamic flow rate, which
eventually leads to restenosis. Nonetheless, restenosis
remains to be a reason for the overall ineffectiveness in
vascular reactivity to control blood flow. An aortic aneurysm
can be dangerous and causes death in case of rupture or
dissection. Pathophysiology of aortic aneurysm includes the
loss of smooth muscle cells in the aortic wall, chronic inflam-
mation, and destructive connective tissue remodeling.13,14
One of the processes that predict the development of
cardiovascular diseases is vascular calcification. Vascular
calcification is common in individuals of 60 and above age,
where an increase in the calcium deposits occurs in the
arteries. Vascular calcification progressively decreases the
arterial and aortic elastance and interferes with the cardio-
vascular hemodynamics. It can result in hypertension,
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cardiac hypertrophy, congestive heart failure, aortic stenosis,
and ischemia. An increase in mineralization causes the for-
mation of atherosclerotic plaques and envisage cardiovascu-
lar morbidity and mortality.15 There are no practical
approaches available to reduce vascular calcification or arter-
ial stiffness. It is very difficult to stop the pathophysiology of
vascular calcification, and this demands early interference in
targeting vascular calcification.16 Vascular calcification is not
only linked with CVDs but also with several other diseases
such as end-stage renal disease.17 Vascular calcification is
one of the leading causes of mortality in patients with chronic
kidney disease.18 There are several traditional and non-tradi-
tional risk factors associated with vascular calcification.
Traditional risk factors are hypertension, diabetes, and dysli-
pidemia (elevation of lipids in the blood). Inflammation and
abnormal mineral metabolism (Hypercalcemia and
Hyperphosphatemia) are non-traditional risk factors. Early
intervention of vascular calcification can prevent the progres-
sion of CVDs.19
In brief, cardiac diseases can define as the abnormal-
ities in muscle repair, morphogenesis, cardiac function,
and cardiac rhythm. In order to treat these diseases, an
alternative and effective remedy needs to be employed,
which involves the direct delivery of cardioprotective
drugs to the cardiovascular system. The need to deliver
these drugs into specific targets has led to the development
of different methods for targeted drug delivery.20 Methods
for preventing CVDs have recommended along with a
healthy lifestyle, which includes non-smoking behavior, a
healthy diet, regular physical activity, weight reduction,
aerobic exercise training, maintaining blood pressure, and
lowering blood lipids.21 However, several therapeutic
methods and drugs available are based on the use of
synthetic compounds. This condition may lead to different
episodes of adverse effects on the body. This topic directs
the researchers to focus on safer and promising therapeutic
methods. In this context, nanotechnology has extended its
heights to the treatment of CVDs. Nanoparticles proved
their role as an effective and reliable platform for the
controlled and targeted delivery of drugs to cure the lipid
disorders, thrombosis, inflammation, and angiogenesis in
atherosclerotic plaques. This review summarizes different
nanoparticle-based drug carriers available so far for the
treatment of cardiovascular diseases.
Different Treatment Strategies for
CVDs
Even though there are recent advancements in the field of
diagnosis, and management of many CVDs, mortality
associated with CVDs remains much higher than cancer
throughout the world. There are several ways to control
and treat cardiovascular diseases. Treatment modalities of
CVDs include control of blood pressure, cholesterol, dia-
betes, weight, and physical activity, depression, and selec-
tion of ideal medications. World Health Organization
(WHO) has recommended population-wide and individual
wise interventions to reduce the burden of CVDs. Tobacco
control policies, applying taxes to decrease the amount of
high fat, sugar and salted foods, tactics to lessen the
alcohol intake, construction of cycle roads, and walking
area to enhance physical exercises has included in the
population interventions (Figure 1). Individual responses
required for people at high risk of CVDs such as having
hypertension and hypercholesterolemia, so that first heart
attacks and strokes can prevent in them. Different kinds of
medication can provide for the secondary prevention of
CVDs associated with other diseases such as diabetes.
These medications include beta-blockers, statins, aspirin,
and angiotensin-converting enzyme inhibitors. Other than
these medications, surgical operations, and medical
devices are also preferred to treat CVDs, such as balloon
angioplasty, heart transplantation, coronary artery bypass,
valve repair, and replacement and artificial heart surgeries.
Medical devices used to prevent CVDs are prosthetic
valves, pacemakers, and patches for heart holes.22 Open
aortic repair, thoracic endovascular aortic repair, hybrid
aortic repair, and combination of open aortic repair and
Monitors health status,
prevent risk factors which
develops CVDs.
(Fetal and infant health,
Smoking habit, Exercise, Diet,
Mental heath and pollution)
Modifying risk factors linked
to disease.
(Hypertension, Diabetes,
Dyslipidemia and Metabolic
syndromes)
Prevention and control of CVD
progression
Figure 1 Current strategies included in CVD interventions.
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thoracic endovascular aortic repair are the known surgery
approaches for treating thoracic and thoracoabdominal
aortic diseases. Yet, a single treatment method has not
customized for the treatment.23
The modern era of cardiac operations adopted invasive
surgeries for treatment. But the paradigm is varying with
the introduction of minimally invasive heart surgery with
small incisions and without cardiopulmonary bypass.
These methods received widespread attention due to
safety, efficacy, and feasibility. Some of the minimally
invasive procedures which reduced post-operative pain,
hospital stay, blood flow, and good cosmesis are hemister-
notomy and right anterior thoracotomy (aortic valve-based
incisions) right minithoracotomy and robotic mitral valve
surgery (mitral valve-based incisions), totally endoscopic
coronary artery bypass grafting. Future technologies such
as endoscopic, percutaneous, and robotic technologies will
reduce the trauma associated with surgery and post-opera-
tive pain in CVD patients.24 Another promising treatment
for CVDs is collectively known as vascular gene therapy.
The possible targets of gene therapy are ischemia, rest-
enosis, thrombogenesis, graft failures, in-stent restenosis,
atherogenesis, and arterial cytoprotection—cardiovascular
gene therapy aids in the overexpression of several thera-
peutically significant proteins and correct genetic pro-
blems. Transfer of vascular endothelial and fibroblast
growth factor genes promoted blood flow and collateral
development in ischemic limb and myocardium. In animal
models of vein graft thickening or restenosis, vascular
gene therapy of genes coding proteins such as vascular
endothelial growth factor, thymidine kinase, retinoblas-
toma, and nitric oxide synthase, cyclin or cyclin-dependent
kinase inhibitors, hirudin, growth arrest homoeobox, fas
ligand and antisense oligonucleotides against transcription
factors exhibited beneficial effects. Even though studies on
gene transfer of vascular endothelial growth factor are
available, further advancements in delivery methods, effi-
cient vehicles, and valid targets are required.25
A large number of drugs are being introduced into the
market for the prevention and treatment of hypertension
and associated CVDs. Complementary and alternative
medicine (CAM) is one of the conventional treatment
modalities among patients with CVD. However, more
than 95% of CAM has suggested to patients with hyper-
tension. CAM includes the integral parts of Traditional
Chinese Medicine (TCM) such as herbal medicine and
acupuncture. Clinical trials showed that acupuncture
could be employed to lower the high blood pressure and
to improve the circadian rhythm of blood pressure of
patients with hypertension. Among all available CAM,
Chinese herbal therapy has gained more popularity.
Many developments occur in the treatment of hypertension
using Chinese herbs and formulations from theory to
experiments and clinical trials. There are some Chinese
patented drugs used for the treatment of hypertension in
clinics such as Niuhuang Jiangya Pill, Yangxue Qingnao
Granule, and Qing Gan JiangYa Capsule. The role of TCM
is limited in the modern hypertension clinical practice and
health care system, even though Chinese herbs can
decrease the elevated blood pressure, improve the endothe-
lial function, regulate the renin-angiotensin-aldosterone
system, protect the target organs and reverse the risk
factors of CVDs.26
TCM is a fascinating feature of Chinese culture, which
combines western medicine as an integrative approach to
treat CVDs. Scientists criticized TCM due to several rea-
sons such as inadequate scientific evidence, lack of suffi-
cient clinical trials, unknown therapeutic mechanisms,
dozens of ingredients in TCM, making it challenging to
study and availability of randomized controlled trials
(RCTs) with small sample size and diverse outcomes.27
Results of some RCTs point out that some of the TCM
therapies might be beneficial to control the risk factors of
CVDs such as hypertension, diabetes, and dyslipidemia.
Also, it indicated that some TCM medications might be
useful as a complementary and alternative approach for
primary and secondary prevention of CVDs.1
There are several single-dose, multiple-dose, or fixed-
dose formulations available to decrease high blood pressure.
The mechanism of action of the single-dose formulation is
the inhibition of a single pathway, which leads to high blood
pressure. Combination therapy has popularized among fixed-
dose formulations, which increase the effectiveness of hyper-
tension drugs by inhibiting multiple pathways. Combination
therapy has suggested that patients who become resistant to
single-dose formulations. Sampatrilat, lleptril, omapatrilat,
gemopatrilat, and fasidotril are brand names of some hyper-
tension drugs which inhibit multiple targets such as an angio-
tensin-converting enzyme (ACE) and neutral endopeptidase
(NEP). These two enzyme inhibitors have used for the treat-
ment of congestive heart failure (CHF), renal failure, and
ischemic heart disease (IHD) through a combination of dose
therapy.5 Precision medicine in CVDs is changing recently,
whereas gene editing and gene-based therapeutics have
applied in the clinics for the treatment of CVD patients.28
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Conventional medicine and synthetic drugs are less in
practice owing to their costs and associated cardiovascular
complications. Natural products have received much atten-
tion as they slow down the progression of CVDs and are
economically attractive. Natural products in CVD medicine
have multi-targeted effects with fewer side effects than syn-
thetic drugs.29 Many bioproducts from plants and phytother-
apy are approved and marketed for the prevention and
treatment of CVDs. Medications obtained from Ginko
biloba, garlic, and Crataegus have suggested for patients
with CVDs. Complementary and alternative medicine
(CAM), along with phytotherapy, has directed for the effi-
cient management of CVDs. CAM continues to control
CVDs by embracing the folk medicine and legacies of our
ancestors. Research in ethnopharmacological medicine
would play a crucial role in CVDs in the future.30
Curcumin, a bioactive component in turmeric, has been
widely studied for its broad therapeutic properties. Curcumin
is known to treat jaundice, cold, hepatic disorders, cough, and
inflammatory diseases. Besides, this phytochemical is
famous for the treatment of CVDs owing to its pleiotropic
actions. This excellent phytochemical suppresses the devel-
opment of drug-induced cardiotoxicity, cardiac hypertrophy,
aortic aneurysm, heart failure, diabetic cardiovascular
complications, atherosclerosis, stroke, and myocardial
infarction.31 Molecular targets of curcumin in CVDs include
histone acetyltransferases (p300), Nuclear factor (erythroid-
derived 2)-like 2 (Nrf2), transcription factor (NF-κB), and
angiotensin II type 1 receptor (AT1R). The application of
curcumin for the treatment of CVDs has limited due to their
low solubility and poor bioavailability in clinical trials. In
this context, researchers had put effort into designing syn-
thetic derivatives of curcumin or drug delivery systems,
which improve bioavailability and solubility. Hence, curcu-
min has utilized as a routine food supplement by considering
its safety level to prevent or treat CVDs.32
Policosanols are fatty alcohols that consist of primary
aliphatic alcohols derived from the wax coating of sugar
cane. These phytochemicals have reported being an essen-
tial alternative with enhanced prevention and treatment
prospects to the common hypocholesterolemic agents.
These are potential agents for patients who either suffer
from medical problems or unwilling to take synthetic
drugs. Approximately 5 to 20 mg/day doses of policosa-
nols have found to be effective in reducing serum lipid
levels, which can develop CVDs in later stages. In addi-
tion to the roles in CVDs, these plant chemicals deliver
beneficial effects to liver function, platelet activity, and
intermittent claudication. Advantages of policosanols
such as enormous availability, low cost, and availability
as food supplements make them to be a potential and
promising alternative to non-natural hypolipemiant
drugs.33
Likewise, polyphenols, the most abundant antioxidant
phytochemicals, are widely studied for their ability to pre-
vent degenerative diseases, especially CVDs. Altogether,
polyphenols have considered for their protective role in
CVDs using human trials.34 It has found that the inclusion
of polyphenol-rich foods in daily meals alleviates the risk
associated with CVDs. The biomarkers of CVDs have
related to lipemia, inflammation, and oxidative stress.
Consumption of polyphenol-rich foods such as tea extract,
pomegranate juice, grape extract, green tea, black tea, wine
polyphenols, red wine, and dealcoholized wine reduced the
development of atherosclerotic lesions in apolipoprotein
E-/- mice and hamsters.35 Other than the polyphenols, anti-
oxidants phytochemicals as a whole can be considered as
potent molecules for the treatment of CVDs. The intricate
etiology of CVDs is characterized by the overproduction of
reactive oxygen species and other free radicals, which may
end up with the disruption of endothelial function and other
deleterious vasodilator effects. There are some flavonoids
from the pulp of Euterpe oleracea that exhibited atheropro-
tective effects in the laboratory. A flavonoid found in Flos
chrysanthemi improved the vasodilator reactivity by alle-
viating the oxidative stress. Quercetin shows protective
properties in animals with atherosclerosis through the inter-
ference with foam cell formation and pro-inflammatory
response.36
Plant-based dietary patterns have always linked with the
treatment of CVDs. A diet containing fruits have a positive
impact on the treatment of CVDs. Epidemiological studies
confirmed that the risk of cardiovascular pathologies is
inversely related to the intake of fruits. Diet covering only
a small amount of fruits is the third most imperative risk
factor of CVDs after high blood pressure and cigarette
smoking.37–39 Fruits which possess cardiovascular protect-
ing properties include grape, pomegranate, blueberry, haw-
thorn, avocado, and apple. The mechanism of actions of
these fruits includes reduction of lipid metabolism and
elevated blood pressure, inhibition of thrombosis, oxidative
stress and inflammatory response, modulation of signaling
pathways, and molecular events associated with the correc-
tion of epithelial function, suppression of platelets function.
It has always recommended studying the mechanism of
action and the protective role of a more significant number
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of fruits in the future owing to their potential candidature for
cardiovascular protection.40
CVDs such as hypertension and heart failure are
related to mitochondrial dysfunction, which results in the
overproduction of free radicals. Improper function of mito-
chondria results in the process of programmed cell death
and finally to CVDs. Hence, control of mitochondrial
dysfunction is a vital process in the design of drugs for
CVDs. The current research and clinical trials are focused
on identifying the role of antioxidant phytochemicals in
controlling mitochondrial dysfunction. Interestingly, sev-
eral studies in animals and humans proved that coenzyme
Q10 could control mitochondrial dysfunction. This coen-
zyme present in the inner mitochondrial membrane is an
anti-thrombolytic and antioxidant molecule, which can
improve hypertension and hyperglycemia. This coenzyme
can be administered alone or along with other drugs for the
treatment of hypertension and heart failure in humans.41
Currently, berries are fetching attraction in the diet chart
and functional foods not only for their pleasing aroma and
appearance but also due to their medicinal properties.
Natural berries such as mulberry, raspberry, blackberry,
cranberry, bilberry, currants, and blueberry have both com-
mercial and nutritional values owing to their protective
and preventive properties for some chronic diseases.
Antioxidant capacity of berries has attributed due to their
high levels of anthocyanins and flavanols. These phyto-
chemicals can scavenge ROS, which plays a vital role in
the prevention of CVDs. Also, they play a potent role in
the regulation of blood pressure, oxidative stress, endothe-
lial function, whole-body metabolism, platelet aggrega-
tion, atherosclerosis and safeguards body from CVDs.42
Rapamycin is a natural product frequently used as an
immunosuppressant after organ transplantation procedure.
Rapamycin complex interacts with its mechanistic target of
rapamycin (mTOR). Hence, the mTOR function has sub-
dued. Rapamycin and its rapalogs have introduced into inter-
ventional cardiology and antitumor therapy after the
discovery of their mechanism. Growing evidence shows
that long-term treatment with rapalogs may lead to dyslipi-
demia after organ transplantation and immunosuppressive
therapy in patients with high risk for CVDs. mTOR inhibi-
tors, along with statins or other drugs, can be employed as a
combination therapy by considering the role of dyslipidemia
as a risk factor in cardiovascular disease.43 Resveratrol, a
non-flavonoid polyphenolic compound, has beneficial effects
on hypertension, stroke, heart failure, atherosclerosis,
arrhythmia, chemotherapy-induced cardiotoxicity, ischemic
heart disease, and diabetic cardiomyopathy. Some of its
beneficial effects are mediated by the activation of cyclic
adenosine monophosphate-activated protein kinase, silent
information regulator 1 (SIRT1), an endogenous antioxidant
enzymes. Besides, the anti-platelet, insulin-sensitizing, anti-
inflammatory, and lipid-lowering properties of resveratrol
have positive effects on CVDs. Clinical evidence of these
drugs still lack which limited its use in clinics.44
Another possible target for the treatment of CVDs is
Endoplasmic Reticulum stress (ER stress). It is a defense
mechanism that identifies unfolded and misfolded proteins
and helps in ER homeostasis. Once ER stress has
extended, vascular cells and cardiomyocytes would
become dysfunctional. It may result in apoptosis and
further lead to the progression of CVDs. In the last five
years, there was an exponential growth in the development
of novel natural compounds (saponins, alkaloids, and
polyphenols) to improve the ER stress along with their
multiple pathogenic pathways, such as apoptosis, ROS
production and inflammation to treat CVDs. Some of the
examples of compounds which mitigate ER stress-
mediated apoptosis, ER stress-mediated oxidative stress
and ER stress-mediated inflammation are baicalein, resver-
atrol, berberine, quercetin, ginsenoside-standardized
extract, anisodamine, notoginsenoside R1, and paeonol.45
A purine nucleoside, adenosine, which regulates a wide
range of cellular and molecular functions of the body, has
enormous therapeutic potential to treat a wide range of
diseases from cancer to CVDs. Modulation of A2 adeno-
sine receptor interaction with adenosine plays an important
role in the regulation of blood pressure, heart rate, and
heart rate variability. It has studied that the dysfunction of
these receptors stimulates CVDs, but the exact pathologi-
cal mechanisms behind these A2 receptors are not avail-
able so far.46
Stem cell transplantation has received much attention for
balancing and regulating cardiac properties. Several studies
indicated that stem cells could improve the heart functions
through their release of paracrine signals and then network-
ing with tissues or organs. Compared to the stem cells, stem
cell-derived exosomes are more stable without immune
rejection, and aneuploidy.47 Exosomes secreted by different
cell lines possess cardioprotective property, direct angiogen-
esis, decrease apoptosis and respond to the stress. Stem cell
transplantation possesses several limitations, such as the
adequate source of stem cells, efficiency of in vitro amplifi-
cation, determination of optimal implementation for the tar-
get stem cell transplantation, etc. Hence, exosomes derived
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from stem cells could serve as a promising alternative for
stem cell transplantation. Exosomes can be loadedwith drugs
for the targeted delivery and effective gene therapy, which is
not possible with stem cells. The exosome-mediated treat-
ment has not widely implemented in the health care system
due to some disadvantages such as complex and cumbersome
extracting procedure of exosomes, a limited quantity of exo-
somes, and the presence of harmful compounds in exosomes.
Also, only a few numbers of exosomes will stay in the site of
injection after intravenous secretion.48
There are conventional drug carrier systems used for
the effective delivery of cardioprotective drugs. Standard
drug carriers for CVDs are tablets or their new liquid spray
through lingual or sublingual administration. These oral
tablets or transdermal patches can exhibit long time
absorption through slow absorption via the digestive tract
and skin. Even though some of the cardioprotective drugs
maintain different types of tablet forms for efficient phar-
macodynamic action. Drug delivery through a stent or
balloon catheter helps to deliver drugs to a small local
target area in coronary interventional therapy. But the
drugs used to treat angina such as beta-blockers, calcium
channel blockers, nitrates, and ranolazine are associated
with adverse side effects. Medications like nitrates, cal-
cium channel blockers, and β blockers used in the treat-
ment of angina pectoris (Heart condition marked by chest
pain due to the less supply of oxygen to the heart) produce
adverse effects such as rash, constipation, nausea, drowsi-
ness, edema, low blood pressure, headache.49 Available
drugs and therapeutic methods for cardiovascular diseases
possess significant side effects with long term usage irre-
spective of their therapeutic potentials such as rhabdomyo-
lysis, renal failure, and hemorrhage.49
Protein conjugates are used for the visualization of
thrombi and targeted thrombolytic therapy. Thrombus spe-
cific antibodies conjugated to a thrombolytic enzyme or
therapeutic agent has recommended in targeting thrombus
to manage inflammation and thrombolysis.50 Other disad-
vantages of conventional drug systems are due to the
monolithic nature, which allows the loading of only one
drug. Thus, multiple medications cannot be loaded on the
same drug carrier, which decreases the overall outcome of
cure.51 Overall, interventional therapy, stem cell transplan-
tation, therapeutic drugs, and other treatment modalities
are not ultimate to treat CVDs. We need to shift the
restoration of heart functions through effective drug deliv-
ery and optimization of therapeutic strategies available for
patients with CVDs. Hence, nanoparticles have introduced
as an excellent and innovative carrier of cardioprotective
drugs for enhanced efficacy with fewer side effects. The
disadvantages of cardioprotective medications such as
nonspecific effects, insolubility, and impermeability to
blood-brain barriers can be eliminated by introducing
nanotechnology.
Emergence of Nanomedicine in
CVDs
Nanoscience and nanotechnology are an emerging field in
communication technology, information, biology, medical
technology, biotechnology, and medicine. Nanoscience is
the study of design, manipulation, production, and appli-
cation of materials with a size of less than 100 nm.
Nanotechnology offered numerous applications in the
field of medicine such as for analytical purposes, imaging,
and diagnosis, treatment procedures such as targeted drug
delivery, gene delivery systems and scaffolds for tissue
engineering.52 Nanoparticles have gained much attention
in medicine owing to their physicochemical properties that
improve biological function (reactivity, roughness, high
surface energy and high surface to volume ratio).
Nanomedicine is a promising field that allows the diagno-
sis, treatment, and control of diseases or disorders to
improve the quality of life and health. Nanoparticles in
medicine provided countless advantages over traditional
and modern medical practices. These advantages include
prolonged half-life of drugs, reduced toxicity, and
enhanced biocompatibility of nanoparticles, and reduced
side effects of drugs by altering the properties of nanopar-
ticles (Figure 2). Moreover, targeted delivery of drugs
using nanocarriers either by active or passive targeting
appears to be a promising method of therapeutics. Active
drug targeting requires the conjugation of drugs to the cell-
specific ligand attached to the nanoparticle. In passive
targeting, a high molecular weight polymer has employed
for the delivery of drug which can permeate and retain in
the tissue for better outcome.53
Nanoparticles of size 1 nm to 100 nm hold unique proper-
ties compared to their larger counterparts. They can cross
biological membranes, cells, and tissues.54 The unique proper-
ties are nanosize, their distinctive quantum size, high surface to
volume ratio, and shape. Nanoparticles can be surface mod-
ified to highlight their physical properties. Monodispersed
nanoparticles have synthesized by controlling the size, shape,
and aggregation of particles, which enables cell internalization.
Nanomaterials have considered as a theranostic, diagnostic,
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drug carrier, and therapeutic agents in various biomedical
applications owing to their unique properties. For example,
high surface to volume ratio of nanoparticles allows the con-
jugation, absorption, or encapsulation of molecules for the
delivery to the target site.55 Drug delivery vehicles are
employed owing to their ability to deliver poorly soluble or
highly toxic drugs to the target areas. Rapid growth occurred in
the field of nanotechnology has answered all the problems
associated with the therapeutic methods of CVDs.
Nanotechnology helps in the early detection and effective
treatment of CVDs, thus reducing the burden on the health
care system. In short, the significant roles of nanoparticles in
CVDs are superior medical imaging, targeted delivery of
drugs, and targeted delivery of nanoparticles to kill diseased
cells. As nanoparticles deliver drugs through blood and tissue,
they can also be eliminated from there efficiently.56 Rapid
developments in the field of nanotechnology enhance the
imaging ofCVDs through the design of capable cardiovascular
molecular imaging probes based on nanotechnology in the
personalized cardio-medicine. Unique features of nanoparti-
cles that enable them as potential agents for cardiovascular
imaging has provided in Figure 3. The promising applications
of these imaging probes inCVDmedicine are due to the ability
of nanoparticles to cross the biological barriers and to accumu-
late at the target site.57 Nano-imaging in cardiology is an
integrative approach for diagnosis and real-time monitoring
during surgery and therapy. Nano-based cardiovascular ima-
ging is interrelated to different fields of diagnosis, surgery, and
therapy. Thus, the nano-based cardiovascular imaging has
categorized into broad areas such as imaging of thrombus,
stem cell, graft, and theranostic approach depending on the
site of detection or the mode of mechanism.58 Different ima-
ging modalities and methods used in cardiology has indicated
in Figure 4.
Theranostic application of nanoparticles in CVDs elim-
inates the gaps between experimental evidence and large-
scale clinical trials. Theranostics in cardiology integrates
imaging and therapeutics by enabling imaging-based thera-
peutic drug delivery systems. There are several nanoparticles
Nanoparticles in 
targeted drug 
delivery
Ease in 
adsorption
Specific targeting
Simple 
encapsulation Bioavailability
Less side 
effects
Enhanced 
solubility 
Figure 2 Advantages of nanoparticle-mediated drug delivery.
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Figure 3 Special features of nanoparticles that made nanomaterials as indispensable
in the cardiovascular imaging.
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employed for diagnostic imaging, drug delivery, and further
assessment of drug efficacy. Nanoparticle-based drug deliv-
ery and its action in the target site has controlled by light,
external magnetic field, or ultrasound, whichminimizes local
and systemic effects.59 Magnetic resonance imaging has
employed for vascular intervention in a site-specific manner.
It has reported that metallic nanoparticles attracted by the
magnetic field identify and impede inflammatory processes
in atherosclerotic plaques.60 Magnetic nanoparticles coated
with natural compounds efficiently used in imaging of
CVDs. For instance, ultra-small superparamagnetic iron
oxide nanoparticles coated with fucoidan (a polysaccharide)
had used for the molecular imaging of thrombus byMagnetic
Resonance Imaging (MRI) arterial thrombus. This contrast-
ing agent was able to image P-selection, adhesion molecule
known as the molecular element of atherothrombotic disease
in a rat model of elastase-induced vascular injury.61
Gold nanorods synthesized by a group of researchers
had used to diagnose and attenuate macrophages through
photodynamic therapy.62,63 Generally, nano theranostics
are categorized into three distinct stages. In the stage I,
nanoparticles-based imaging agents are used to evaluate
the efficiency of conventional therapy. Stage II, imaging
agents are integrated to study the efficacy of nanoparticle-
mediated therapy. Stage III, nanoparticle-based imaging is
used to evaluate the effectiveness of nanotherapy.64
Commonly, nanomedicine in cardiology deals with four
main areas that control and/or aids in the management of
CVDs. These areas of nanotechnology are molecular ima-
ging, targeted drug delivery, tissue engineering, and diagnos-
tics. Nanocarriers hold several advantages such as the
controlled release of drugs to the targets, enhanced bioavail-
ability of therapeutic agents, and targeted delivery of drugs
(Figure 5). There are several types of drug delivery systems
or devices available for the management of CVDs. Some of
the possible and widely studied drug carriers are liposomes,
polymeric nanoparticles, micelles, dendrimers, etc. An ideal
drug carrier has defined by its non-toxic nature, ability to
escape from the host immune system, biodegradability, bio-
compatibility, non-immunogenic properties, and drug target-
ing properties.49 Also, the small size of nanoparticles allows
them to pass through the cell membrane or blood-brain
barriers for the targeted delivery of drugs of interest.
Controlled and targeted delivery of drugs has achieved
through optimizing several parameters such as temperature,
enzyme activity, pH, stimuli (ultrasound, magnetic field,
infra-red) etc.65 Some nanoparticles can be loaded with a
huge number of drugs for a diagnostic or therapeutic
approach such as in polymeric nanoparticles and liposomes.
Other nanoparticles require additional functional ligands to
conjugate the drugs. Nanoparticles have used as multifunc-
tional agents for diagnosis and treatment of CVDs owing to
Nanoparticle mediated delivery
Nanoparticle based 
diagnostic imaging
Cardiac protection
Imaging modalities
Nuclear imaging technique
Positron emission tomography (PET)
Optical imaging
Ultrasound imaging(US)
Magnetic Resonance Spectroscopy and 
Magnetic Resonance Imaging (MRS 
and MRI)
Computed Tomography Imaging(CTI)
Nanoparticles
Figure 4 Nanoparticle-mediated diagnosis and imaging of CVDs.
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their high surface ratio, which allows surface modification.
Surface modification of nanoparticles with different func-
tional moieties such as small molecules, peptides, aptamers,
and antibodies allowed the modulation of their biodistribu-
tion, and their targeted delivery.66 Liposomal platforms are
multifunctional nanomaterials which can be used as efficient
drug carriers and molecular imaging probes. Ligand
bound liposomes are employed in cardiovascular imaging.67
Nanocarriers allow the conjugation or encapsulation of
drugs, which enhances the solubility of drugs, reduces sys-
temic toxicity and protects frommetabolism and excretion.68
The rational involved in the design of nanocarriers for cardi-
ovascular medicine are multi-criteria design. This multi-cri-
teria for design and development of nanocarriers include
product physicochemistry, quality of the ingredient such as
safety, pyrogen content and serializability, manufacturability
including process cost, cost of goods, stability, biocompat-
ibility, toxicity, efficacy, pharmacokinetics, biodistribution
and finally clinical acceptability.69
Some of the nanocarriers developed for the treatment of
cardiovascular diseases are discussed here before going into
detailed perspectives. Among all nanocarriers, polymeric
nanoparticles are ideal nanodevices for targeted drug
delivery.70 These smaller particles exhibit higher uptake in
the walls of the artery with sustained release of the drugs to the
target site. Sustained release of drugs has determined by their
various characteristics such as cross-linking, molecular
weight, and monomer ratio. Poly (lactic-co-glycolic acid)
(PLGA) nanoparticles are the commonly used biodegradable
polymer nanoparticles. This polymer nanoparticle degrades as
soon as the drug has delivered to the site. For example,
sirolimus delivered through PLGA nanoparticles (treated
with gelatin) sustained in the system for 50 days. Delivery
of nanoparticle coated with drugs using catheter helps in the
penetration of nanoparticles to the arterial wall due to the
pressure. It acts as the drug reservoir for the treatment, as
the nanoparticle gets stuck in the wall once the pressure is
released. The delivery of drugs using a catheter has an advan-
tage over the drug-eluting stents. It is because inflammatory
response is generated inside the system by the reaming poly-
mer scaffold as soon as the drug has depleted. Drug-eluting
stents have used for the delivery of drugs from polymer or
stents71 (Figure 6). Different types of nanocarriers used for the
targeted delivery of cardioprotective agents have described in
Table 1.
Exosomes derived from stem cells are nanosized vesicles
exploited widely for their drug-carrying capacity. Stem cell-
derived exosomes are essential in the delivery of mRNA,
miRNA, and proteins to the recipient cells. The therapeutic
potential of exosomes in CVDs includes their cardioprotection
activity and drug delivery properties (Figure 7). In brief, these
are called natural liposomes due to their similarity in tissue
targeting and drug delivery as that of liposomal drug delivery
systems. In addition, exosomes are used as diagnostic markers
in CVDs.88 Researchers studied several biomimetic nanocar-
riers for the treatment of CVDs. These biomimetic nanoparti-
cles are involved in the apoptosis of macrophages and smooth
muscle cells, which will benefit in the rupturing of plaques.
High-density lipoprotein mimicking nanoparticles can target
the mitochondrial membrane potential that happens during
apoptosis to identify the susceptible plaques. These biomi-
metic nanoparticles contain a core of biodegradable poly
• Less targeting
• Side effects
• Poor bioavailability
• Low solubility
• Non specific activity
• Impermeable to blood-brain barriers
• Short half life
• Passive or active drug targeting
• Little  or no side effects
• Prolonged half life
• Enhanced biocompatibility
Cardioprotective 
drugs Nanoplatforms with loaded drugs
Heart showing 
injured tissues
Figure 5 Schematic representation showing a general treatment method and targeted drug delivery using nanoplatforms to damaged cardiovascular tissues.
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(lactic-co-glycolic acid), triphenylphosphonium, and choles-
teryl oleate. Agents present in the nanoparticles can detect the
collapse of mitochondrial membrane potential. A-I mimetic
4F peptide anchored to the lipid layer can enhance the passage
of cholesterol from the lesions. Furthermore, quantum dots
incorporated into the core improves optical imaging.89,90
Synthetic High-Density Lipoprotein (HDL) -PLGA
biomimetic nanoparticles have developed to accumulate
in the macrophages and monocytes of the aorta. These
HDL nanoparticles are having PLGA, apolipoproteins
and lipids 1-stearoyl-2-hydroxysn-glycero-3-phosphocho-
line/1,2-distearoyl-sn-glycero-3-phosphocholine. These
HDL nanoparticles for the quick detection of vulnerable
plaques has used as preventive, therapeutic methods for
atherosclerosis. Difficulty with such nanoparticles is asso-
ciated with their scale up production for clinical/market
trials due to their complex methods of construction.91 Hu
et al, 2015 formulated nanocarriers using biomimetic
nanoparticles covered with platelet membranes.92 These
HDL nanoparticles of size 100 nm coated with platelet
membranes have found to be promising drug carriers for
the treatment of CVDs, especially atherosclerotic diseases.
This type of nanoparticles utilizes the ability of HDL and
platelet membranes to target natural atherosclerotic
plaques and their selectivity to deliver to the biological
motifs, damaged human and rodent vasculatures.
Furthermore, they can direct the clearance of plaques
from pre-atherosclerotic and atherosclerotic areas. Even
though these nanoparticles have able to target plaques,
their ability to eliminate the plaque is weak completely.
Thus, diagnostics and therapeutics should be considered
concurrently when designing these nanodevices for the
elimination of plaques in the future.92,93 There are nano-
carriers of thrombus-specific tissue plasminogen activator
(tPA), which enhances the efficacy of thrombolysis and
inhibits serious bleeding complications. Nanocarriers are
developed to eliminate the shortcomings of this tPA, such
as short life span (approximately 5 minutes), rapid inacti-
vation by plasminogen inhibitors 1 in the blood, and
requirement of large doses. For example, urokinase was
delivered to a rat model of the autologous carotid artery
and left jugular vein thrombosis through dextran-coated
magnetic nanoparticles. Urokinase was conjugated to
nanoparticles through primary amine ligands and showed
a fivefold higher thrombolytic activity in model animals
than the free plasminogen activator.94
The chelating agent, ethylenediaminetetraacetic acid
(EDTA), can resorb calcium mineral deposits, but the sys-
temic delivery of it may result in side effects. Nanoparticle-
mediated delivery of chelating agents has recommended as it
holds an effective treatment modality.95 In a study, targeted
delivery of Matrix metalloproteinases (MMP) inhibitors has
carried out using Poly Lactic Acid (PLA) nanoparticles con-
jugated with an anti-elastin antibody to a rat model of abdom-
inal aortic aneurysm. Nanodelivery of batimastat (MMP
inhibitor) prevented aneurysmal growth, vascular calcifica-
tion, inhibited the activity of MMP, and degradation of
elastin.96 Nosoudi and co-workers employed a dual therapy
with targeted delivery of EDTA and pentagalloyl glucose for
the removal of mineral deposits and to restore elastic lamina.
The dual delivery of chelating agent and polyphenol reversed
the aneurysm development through reduced macrophage
recruitment, MMP activity, degradation of elastin and arterial
calcification.97 Vascular calcification was reversed in a rat
model of chronic kidney disease when supplemented them
along with the targeted delivery of EDTA using anti-elastin
conjugated albumin nanoparticles.95 One of the clinical trials
of nano-drug platforms was successful and named as
Abraxane (nanoparticles conjugated with albumin-bound
paclitaxel). Abraxane treatment has found to be tolerated up
to 30 mg/m2; however, additional studies are required to
identify the effects of nanoplatforms delivered by intravenous
Advantages
Targeted
delivery to the
site of
cardiovascular
injury
Enhanced
efficiency of
drugs/dose
No adverse
effects and
systemic
toxicity
Combined for
treatment,
diagnosis and
imaging
Limitations
Lack of data
about clinical
trials and
safety
Tedious
methods for
characterizatio
n and purity
analysis
Cost of scale
up production
Long term
stability of
drugs
Figure 6 Advantages and disadvantages of nanoparticle-mediated drug delivery in
cardiovascular diseases.
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and intracoronary administration.98 There are less clinically
approved nanomedicine in the treatment of cardiovascular
diseases. Solid lipid-based nanoparticles loaded with carvedi-
lol (β adrenergic receptor blocker) and liprostin (a Phase 3
clinical trial drug) was clinically tested to improve their bioa-
vailability and to treat peripheral artery disease. Dendrimer
formulation of candesartan (clinically approved angiotensin
receptor blocker) achieved an enhanced drug solubility
extending its use in targeted delivery to injured cardiac
tissues.2
As curcumin is a natural compound widely used for
atherosclerosis from past so many years, curcumin nano-
particles have developed to enhance the efficacy of curcu-
min. There are several studies showing curcumin
nanoparticles applied in the treatment of CVDs. But its
clinical usage is limited by fast systemic exclusion, alka-
line pH degradation, low gastrointestinal absorption, rapid
metabolism, and low water solubility. Even though curcu-
min is the right candidate for suppressing myocardial
tissue oxidative stress, curcumin nanoparticles showed
enhanced cardioprotection than curcumin. Curcumin nano-
particles limit myocardial damage in acute myocardial
infarction (AMI). These nanoparticles protected isoproter-
enol-induced myocardial infarction in rats by altering elec-
trocardiogram and myocardial tissue oxidative stress.99 In
a rat model of isoproterenol-induced MI, curcumin nano-
particles exerted a better cardioprotective effect than cur-
cumin. It also showed improved myocardial function and
reduced heart injury after MI. Enhanced effects of curcu-
min nanoparticles are in accordance with their enhanced
antioxidant activity and reduced amount of pro-inflamma-
tory cytokines and matrix metalloproteinases in serum.100
The impact and incidence of MI are higher in diabetic
patients than in healthy individuals. Curcumin nanoparti-
cles showed enhanced cardioprotective effects in a rat
model of isoproterenol-induced AMI with diabetes melli-
tus when compared to curcumin. Also, these nanoparticles
could be employed in the treatment of AMI developed in
diabetic patients due to their antioxidant and anti-inflam-
matory nature.101
Nanoparticles for the Treatment of
Coronary Artery Disease (CAD)
The clinical applications of nanomedicine in the field of
cardiovascular diseases are limited and are in clinical
trials. Coronary artery disease has occurred from the
build-up of the atherosclerotic plaque on the inner wallT
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of the coronary artery. It appears in the stenosis of the
cavity, which reduces the compliance of the vascular wall.
Thus, the blood supply to the myocardium has disrupted
partially.102 A chronic disease, atherosclerosis has charac-
terized by the thickening of the arterial wall and inflam-
mation of plaques.103 Heart attack occurs when coronary
arteries have obstructed by atherosclerosis. During this
condition, a sequence of the intricate and interlocked phy-
siological process take place involving many cells, extra-
cellular matrix, and cytokines that are triggered by
hypoxia of cardiomyocytes. It, in turn, directed to the
loss of cardiac function and followed by the replacement
of myocardium by fibrous scars.104 Coronary thrombosis
happens during the shredding or rupture of atherosclerotic
plaques. Plaques are vulnerable and shreds due to specific
characteristics such as reduced smooth muscle cells and
extracellular matrix, plaque bleeding and calcification and
appearance of numerous inflammatory cells and large
necrotic core with flimsy fibrous cap.105,106 Nanoparticles
can be applied for the treatment of atherosclerosis by
improving their circulation in the whole body, enabling
better solubility of drugs, reducing the required amount of
drugs, decreasing the cytotoxicity of drugs, enhancing the
targeted delivery of drugs at specific concentrations and
merging both the diagnostic and treatment methods to
develop a better theranostics.107 Nanoparticle-mediated
drug delivery and treatment for atherosclerosis and asso-
ciated complications have focused in resolving inflamma-
tion and defective efferocytosis, preventing plaque
neovascularization, targeting macrophages, altering lipid
metabolism, preventing neointimal growth and targeting
thrombosis (Figure 8).108 Liposomal preparation of
bisphosphonate alendronate decreased the neointimal for-
mation and then suppressed the circulating monocytes in
rabbits with iliac artery stenting. Liposomal alendronate
has found to be safer in early clinical trials for infusion at
the time of percutaneous coronary intervention.109
Statins are commonly used drugs for the treatment of
coronary artery diseases. In general, the use of statin is
limited recently due to their high dose therapy associated
with systemic side effects.110 Nanometer-sized vesicle
loaded with pravastatin was prepared after functionalization
by oligonucleotides to target the macrophages. These
Collagen synthesis
Angiogenesis
Neovascularization
Proliferation of cardiomyocytes
Cardiomyocyte survival
Improved cardiac function
Fibrosis
Inflammation
Vascular remodeling
Apoptosis
Stem cell
derived
exosomesDifferent types of stem
cells
CVDs
Figure 7 Applications of exosomes derived from stem cells in the treatment of cardiovascular diseases.
Targets 
thrombosis 
Resolves 
inflammation
Targets 
defective 
efferocytosis
Prevents 
plaque 
neovasculariza
tion
Targets 
macrophages
Alters lipid 
metabolism
Prevents 
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Figure 8 Several potential targets for the nanomedicines in the treatment of
cardiovascular diseases.
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nanocarriers were found to be promising alternatives that
allow a high dose therapy with enhanced efficacy and less
toxicity of statins in the neighboring tissues.111 Likewise,
paramagnetic nanoparticles are used for the delivery of
fumagillin (antiangiogenic drug) targeted by integrin,
which exhibits a decrease in the systemic adverse effects.112
Nanocarriers are thought to alter lipid metabolism through
RNA interference. They directly target the metabolism of
liver cholesterol. Targeting apolipoprotein B may benefit
from lowering the LDL and total cholesterol levels.113,114 In
monkeys and rodents, silencing of their apoB in hepatocytes
using liposomal preparation of apoB-small interfering RNA
resulted in the reduction of total cholesterol and LDL.115
LDL cholesterol can be reduced in a potent manner through
the siRNA silencing of proprotein convertase subtilisin/
Kexin type 9 (PCSK9) (inclusion). In the above study,
second-generation lipid nanoparticles loaded with siRNA
has targeted to PCSK9 in individuals with high LDL cho-
lesterol levels. These lipid-based nanoparticles used for the
silencing of RNA are called lipidoids. Lipidoids are used for
the suppression of PCSK9 synthesis in the liver and cause
rapid effects after the administration of a single dose.
Clinical trials of inclusion are ongoing on rodents and
monkeys, where it reduced the LDL levels in the clinical
phase for at least six months. Clinical Phase III trials are
still in progress, and it is expected to bring revolution in
cardiovascular medicine.116 ApoE-/- mice fed with the
high-fat and induced atherosclerotic plaques have treated
with antibodies conjugated to copper sulfide nanoparticles.
Antibodies have synthesized against an ion channel from
the transient receptor potential vanilloid subfamily 1
(TRPV1) expressed in vascular smooth muscle cells.
These ion channels have opened with the increase in the
temperature that causes the influx of calcium ions and
activates autophagy in the smooth muscle cells. Also, ion
channels decrease the accumulation of lipids and inhibit
the formation of foam cells. Copper sulfide nanoparticles
provide an effective and non-invasive treatment method
for CVDs owing to their absorption in the near infra-red
range and generate a photoacoustic signal that helps in
treatment.117
Patients are suffering from peripheral artery disease dis-
play difficulty in revascularization procedures owing to the
high rate of restenosis and re-intervention. Thus, nanother-
apeutic methods are developed, which ultimately enhance the
retention of drugs in the plaques and local vascular bed.
These nanocarrier methods include the delivery of drugs
through catheters fixed in stents. Paramagnetic nanoparticles
loaded with rapamycin are used to treat balloon injured
arteries of female rabbits. These nanocarriers enhance the
targeted delivery of drugs and improve imaging throughMRI
due to the high contrast potential of nanoparticles. It also
enables the local infusion of nanoparticles to the arterial wall
with functional retention capacity and decreases the neointi-
mal formation.118 Some researchers utilized the tunable
properties of the nanoparticle to encapsulate with nitrogen
gas and RNA interference compounds119 for the local deliv-
ery of drugs to the arterial wall. Nitric oxide is a gas with
potential therapeutic effects of anti-inflammation, anti-pro-
liferation, vasodilation, anti-thrombosis, and anti-atherogen-
esis. Systemic delivery of nitrogen gas provides less low
bioavailability with adverse effects. Nitrogen gas loaded
into echogenic liposomes with co-encapsulation of argon
was used for controlled delivery of bioactive gas to inhibit
intimal Hyperplasia (thickening of the blood vessel).120
Nanoparticle-mediated delivery of drugs has formulated to
target thrombosis. Thrombus targeted nanoparticles are
enabled by platelet activation, coagulation cascade, and
fresh thrombus for the delivery of thrombolytic agents, direct
thrombin inhibitors, urokinase, streptokinase, and anticoagu-
lants (example tissue-type plasminogen activator, tPA).
Intravenous injection of thrombus targeted nanoparticles
(encapsulated with von Willebrand factor binding protein)
with tPA results in the reperfusion and vessel recanalization
in most of the swine. Nanoparticles have designed with a
greater offloading, controlled release of tPA, and thromboly-
tic activity at the affected artery using transthoracic
ultrasound.121 Thus, nanoparticles are potent nanodevices
for anticoagulation and reperfusion therapy with diminished
bleeding consequences. Theranostic nanoparticles loaded
with anti-thrombin can be directly used for the attenuation
of plaque coagulant activity in the damaged arteries of the
apoE-/- mice model. These nanoparticles have able to retain
in the plaques and cause prompt inactivation of locally pro-
duced thrombin. Anti-thrombin theranostic nanoparticles sti-
mulate the stability of plaques. Besides, the expression of
plaque inflammatory molecules has reduced, and damaged
vascular endothelium has repaired through the inhibition of
plaque thrombin.122
There are inflammatory macrophages or monocytes that
perform a significant role in the suppression of atherosclero-
sis and rupture of plaques. Bioabsorbable nanoparticles can
be utilized for the targeted delivery of pioglitazone to the
circulating monocytes or macrophages. This causes the reg-
ulation of inflammatory reactions and further prevents the
plaque ruptures.123 Immune cells always hold an endurable
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role in the progression of atherosclerosis. Nanoparticle
library has generated for the treatments which utilize various
physical and chemical properties of nanoparticles and differ-
ent types of immune cells. The high density, endogenous
lipoprotein-based nanoparticle library is prepared in such a
way that it achieves the targeted delivery of drugs to the
macrophages in the plaques.124 Hirulog (inhibitor of throm-
bin) obtained from hirudin has conjugated to the micellar
nanoparticles, which inhibited the formation of fibrin clots
after coronary artery occlusion. This coronary artery occlu-
sion has mainly caused by atherosclerotic plaque degenera-
tion and rupture.86 Pre-resolving nanomedicine is having
promising applications in the treatment of atherosclerosis.
Researchers synthesized nanoparticles containing anti-
inflammatory peptides such as Ac2-26. They displayed
enhanced resolution and assisted in neutrophil recruitment
for an improved targeted delivery.125 Restenosis is carried
out after coronary artery angioplasty and is influenced by
mechanical injury, delayed endothelial healing, and inflam-
matory responses. Long term success of stent placement has
determined by the inhibition of vascular thrombosis and
restenosis.126 Nanoparticles such as PLGA has appeared to
be a promising alternative for the improved intra-arterial
localization of drugs in restenosis.127 These limitations can
be addressed by the drug-eluting stents coated with nanopar-
ticles. These particular stents can even enhance the therapeu-
tic effects of ineffective drugs.128 Nanodevices has designed
with a nanoparticle-drug eluting stent for the prevention of
restenosis and improved endothelial recovery. For instance,
sirolimus/pitavastatin nanoparticle-eluting stents are pre-
pared and showed a reduction in in-stent restenosis. Early
endothelial healing has occurred only in the case of sirolimus
nanoparticle-eluting stents.129
A group of researchers has used polymeric nanoparticles
(PLGA) for the treatment of plaque destabilization. They
found that nanoparticles are partially delivered to the plaques
by the phagocytosis of monocytes or macrophages. It has
also confirmed that the nanoparticles have delivered to the
lesions owing to their permeability. PLGA nanoparticles
coated with pitavastatin (HMG CoA reductase inhibitor)
reduced the infiltration of circulatory monocytes/macro-
phages and destabilization of plaques in the arteries.
Liposomal delivery of siRNA against the CCR2 receptor to
the spleen, liver, and bone marrow was successful.
Furthermore, it inhibited the infiltration of monocytes
to the aorta and plaques.130 Pioglitazone, a clinically
approved drug activates peroxisome proliferator-activated
receptor gamma (PPARg). Oral administration of drugs
causes a reduction in the macrophage content and matrix
metalloproteinase activity in a murine model of athero-
sclerosis. Other than their anti-diabetic activity, pioglita-
zone has a beneficial effect on macrophage polarity. PLGA
nanoparticles loaded with pioglitazone were employed in
the murine model to study their effect on atherosclerosis.
Activation of the receptor enhanced the differentiation of
macrophages. Here, the targeted delivery of pioglitazone
skews the monocyte and/or macrophage polarity and reg-
ulates inflammation in a murine model. Long term therapy
(4 weeks) of the drug significantly reduced the number of
buried fibrous caps and their thickness which is a surrogate
marker of plaque rupture.130
Nanoparticles for the Treatment of
Ischemic Heart Diseases
One of the severe ischemic heart diseases is myocardial
infarction, which leads to heart failure and, ultimately, to
death. Cardioprotective drugs that have applied in the treat-
ment increase angiogenesis promote cardiomyocyte survi-
val, improve heart function, restrain inflammation, and
myocyte activation, and eventually prevent fibrosis. In
short, all the treatment and therapeutic agents are involved
in the protection and preservation of cardiac function. Virus
mediated gene transfer and therapy are successful and well-
known in promoting cardiomyocyte survival and cardio
function in mice. Yet, virus-mediated gene therapy is lim-
ited to animal studies and clinical trials owing to their safety
concerns. Safety issues related to the treatment are their
immunogenicity, unpredicted insertion site in the genome
of humans, and poor targeting efficiency.131 Nanoparticles
mediated gene delivery to improve cardiac function pro-
vides a promising alternative in the field. Nanoparticles
have used for gene delivery due to their small size that
enables a smooth and efficient penetration to the cells.
Specific tags can be attached to nanoparticles through a
covalent bond for better absorption by the target cells.
Another advantage of nanoparticles over viruses is their
faster synthesis methods and their ability to cluster recep-
tors for the activation of signaling pathways.132,133 There
are entrapping systems and surface binding systems of
nanoparticles that have used as carriers for DNA or RNA
delivery. The entrapping system is a reservoir type nano-
sphere system and protects the gene of interest from degra-
dation. The surface binding system supports the ionic
interaction between the anionic nucleic acid and cationic
polymer. PEGylation can be used for the delivery of a gene
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to vascular tissues. Researchers constructed PEG–POD/
DNA by linking a peptide to the PEG for the ocular deliv-
ery. Reduction of PEG-POD/DNA results in the induction
of a twenty-one-fold increase in the transgene expression. It
ultimately leads to the decline (50%) in the choroidal neo-
vascularization when tested in vivo.134 Mannosylated chit-
osan nanoparticles are excellent carriers for DNA and
siRNA delivery and, instead, are readily taken up by the
macrophages. Thus, the application and future perspectives
of mannosylated chitosan nanoparticles for subduing
inflammation and reducing myocardial infarction await
further studies.135,136
Placental growth factor (PIGF) is useful to stimulate
angiogenesis and improve cardiac function at the site of
damage that occurred due to acute myocardial infarction.
Chitosan-alginate nanoparticles have designed for the effec-
tive delivery of PIGF with biocompatibility, non-toxic and
biodegradable properties. Chitosan-alginate nanoparticles
have found to be an excellent vehicle for PIGF delivery by
intramyocardial injection to improve the benefits of PIGF at
the site of injury. These nanoparticles can protect the growth
factor from enzymatic degradation before its delivery to the
tissues.137 Endogenous angiotensin II is vital for the delayed
phase of an injury, recruitment of monocytes, and finally,
inflammation of myocardium occurs. Thus, intravenous
injection of bioabsorbable nanoparticles (PIGA) loaded
with irbesartan (antagonist of angiotensin II type 1 receptor)
at the time of reperfusion causes the inhibition of monocyte
recruitment and then reduces themyocardium infarct through
anti-inflammatory mechanisms. Insufficient local drug accu-
mulation during reperfusion time was observed in clinical
studies and demanded the development of effective delivery
systems for a better clinical outcome.138 Injectable hydrogels
have formulated for the treatment of acute myocardial infarc-
tion. Delivery of drugs through injectable hydrogels formed
by nanofibers is one of the non-invasive methods which
reduce the recovery time required for patients and also the
occurrence of infections. Hydrogels such as RAD16-II
loaded with vascular endothelial growth factors has injected
into animals with myocardial infarction for the intramyocar-
dial drug delivery. Systemic delivery of vascular endothelial
growth factor using liposomes resulted in the improvement
of the heart function and vascular density.139
Mitochondrial dysfunction can lead to cardiac diseases.
Hence mitochondria are considered as an important thera-
peutic target to prevent heart failure and to limit the myocar-
dial infarct size in patients with ischemic heart disease. There
are several mitoprotective drugs (cyclosporine-A (CsA) or
TRO40303) designed to target cardiac mitochondria. The
drawbacks of these mitoprotective drugs are less permeabil-
ity through the plasma and mitochondria membrane.
Nanoparticles have introduced along with mitoprotective
drugs to solve the hurdle of reduced permeability. PLGA
nanoparticles carrying mdivi-1 (small molecule inhibitor of
mitochondrial fission protein) to mitochondria protected
H2O2 mediated death of rat cardiomyocytes.
140 Another
drug, CsA encapsulated with PLGA nanoparticles reduced
myocardial infarct size, protected mitochondrial permeabil-
ity transition pore opening and prevented ventricular remo-
deling in a perfusion mice model.141
Nanoparticles as Drug Delivery
Agents in the Treatment of CVDs
Gold Nanoparticles
Gold nanoparticles are one of the widely used nanocarriers
for the delivery of cardioprotective drugs. The application
of gold nanoparticles with existing clinical drugs has sug-
gested as a novel approach with enhanced potential in the
treatment of heart diseases. Gold nanocarriers have broadly
used metal nanoparticles owing to their ease in synthesis,
low toxicity, low immunogenicity, and stability.142 It has
been reported that clinical drugs become more efficient and
accurate in their conjugated form. Simdax is a clinically
approved drug for the treatment of heart disease. Simdax
conjugated on gold nanoparticles (AuNPs) exhibits cardio-
protective effects in rats with doxorubicin-induced heart
failure. The cardioprotective properties of gold nanoconju-
gates and simdax are superior to their counterparts owing to
the enhanced targeting of gold nanoconjugates to the
injured tissue.79 The β blockers exert beneficial effects on
the hyperactivity of the sympathetic nervous system of the
volume overloaded heart failure. Metoprolol is one of
the widely used β blockers and conjugated with AuNPs
for the improved delivery to the cardiac tissues.
Metoprolol preferentially targets β1 receptors, and the con-
jugates show double efficiency in targeting the volume
overloaded heart failure tissue. These conjugates can be
employed in the clinical practice as it displays little adverse
effects on other organs.143 Diabetic cardiomyopathy can be
treated with miR155-AuNPs. It is a disease commonly
found in women after menopause, where the disease symp-
toms worsen by estrogen deficiency.144 Generally, an exces-
sive number of pro-inflammatory type 1 macrophages over
anti-inflammatory type 2 macrophages were found in the
hearts of diabetic mice. Additionally, an increase in the cell
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apoptosis, fibrosis, reactive oxygen species production, and
cardiac hypertrophy had observed in the hearts of ovariec-
tomized diabetic mice. In vivo delivery of miR155-AuNPs
conjugates significantly increase anti-inflammatory type 2
macrophages, and decrease the intensity of inflammation. It
is, in turn, reduces cell apoptosis and finally leads to the
restoration of cardiac function.77
Cardiac tissue engineering is an emerging therapeutic
method for the treatment of CVDs. Tissue repair or tissue
regeneration combines different combinations of nanomaterial
and biomaterials with engineering strategies. Generally, car-
diac regenerative biomaterials have coated electrically active
nanoparticles to target the cardiac tissues. In a study, the
injection of hydrogels fabricated from electrically active
gold and laponite nanoparticles loaded with extracellular
matrix improved the biological and functional properties of
cardiomyocytes. Gold or laponite nanoparticles with extracel-
lular matrix-hydrogel enhanced the compatibility of cardiac
cell and phenotypic maturation of cardiac-specific proteins.
For example, nanoformulations used in the above study
improved the expression of cardiac-specific markers such as
SAC, Cx43, and cTnl. It confirms the potent applications these
hydrogels in the targeted delivery of biologically active mate-
rials for the cardiac tissue engineering of infarcted myocar-
dium. The functional properties and electrical conductivity of
biomaterials are maintained by the incorporation of nanofor-
mulations into the cardiac tissues. These nanoformulations
decrease the porous structures in the hydrogel so that a favor-
able environment has provided for cardiomyocytes.145
Gold nanoparticles are proven promising nanomaterials
for drug delivery without causing toxicity in the healthy
tissues. Gold nanoparticles have used in the laboratory for
the treatment of AMI; however, clinical trials and future
experiments are still to be explored in the future. AMI may
lead to other complications such as necrosis and apoptosis of
cardiomyocytes, propagation of fibroblasts, conversion of car-
diomyocytes to myofibroblasts, deposition of collagen in the
myocytes, and cardiac hypertrophy. Hypertrophy of cardio-
myocytes can lead to heart failure. However, gold nanoparticle
conjugates or alone possess beneficial effects in AMI, which
further prevents all other complications. PEGylated gold
nanoparticles of size 10 nm protected have able to reduce
the size of the infarcted heart through the inhibition of necrosis
and apoptosis of cardiomyocytes.146 Moreover, they can
decrease the collagen deposition and then inflammation.
Thus, the study suggests the utilization of gold nanoparticles
alone or its nanoconjugates for the treatment of CVDs.147
Photodynamic therapy and sonodynamic therapies are
recommended for the treatment as they possess improved
cure rates and reduced adverse effects. Certain drugs such as
precursors of porphyrins with metal nanoparticles synthesized
by photoreduction methods can target and destroy the patho-
genic tissues. These nanoparticle formulations induce cell
death by the production of reactive oxygen species and
DNA damage. A group of researchers synthesized aminole-
vulinic acid (porphyrin IX precursor)-metal nanoparticles
(gold nanoparticles or/and iron oxide nanoparticles) through
the photoreduction method. Nanohybrids interfere with the
selectivity of iron transport across the inner membrane of
mitochondria. Thus, these nanohybrids act as a novel diag-
nostic and therapeutic method for CVDs, which selectively
and effectively destroy macrophages.148
Ischemia causes hindrance in the blood flow and
damages the downstream tissues owing to the less avail-
ability of oxygen and nutrients. Therapeutic angiogenesis
occurs through the process of angiogenesis, where new
blood vessels are built by evolving and diverging from the
available blood vessels. Therapeutic angiogenesis is used to
treat ischemia through the delivery of various growth fac-
tors such as vascular endothelial growth factors. Delivery of
these growth factors have been shown to be less effective in
the clinical trials such as short half-life of growth factors in
the blood circulation, lack of specific targeting and the
inability of growth factors to retain in the circulation for
days to weeks, which is essential to avert the deterioration
of new vessels. Gold nanoparticles act as an excellent pay-
load for imaging and targeted delivery of vascular endothe-
lial growth factors to ischemic muscle tissues in the murine
hindlimb ischemic model. Murine model of ischemia is a
typical model for peripheral artery disease. Gold nanopar-
ticles of size below 200 nm are able to accumulate in the
ischemic muscle. Hence, therapeutic targeting of exogenous
growth factors to the tissues exhibits a rise (1.7-fold rise) in
the blood perfusion. Gold nanoparticles target the ischemic
muscle tissues through their enhanced permeability and
retention effect. It promotes the recovery of a large volume
of ischemic tissue along with enhanced angiogenesis due to
the delivery of exogenous growth factors.76 Growth factors
were successfully delivered through gold nanoparticles to
modify the damaged heart tissue in coronary artery disease.
Whereas traditional intravenous administration methods
possess difficulties in targeting these growth factors to
damaged tissue.77 Gradually, gold nanoparticles have
proved as one of the most promising drug carriers for
accurate delivery to injured heart tissue. Gold nanoparticles
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conjugated with clinically approved drugs enhanced the
efficacy of these drugs to treat heart diseases.139,149
Liposomal Platforms
Liposomal delivery systems are robust platforms for site-
specific delivery of therapeutic agents. Liposomes are
spherical nanoparticles that possess a bilayer structure
made of natural lipids or synthetic cholesterol. These
spherical structures have a hydrophilic core surrounded
by a hydrophobic membrane. They can be conjugated
with proteins or peptides for improved delivery to the
tissues or to produce biological benefits.150,151 The first
therapeutic liposomal drug approved by the Food and
Drug Administration (FDA) and prescribed for the patient
is liposomal doxorubicin (Doxil). Doxil is used for the
treatment of several cancers but minimizes the cardiotoxi-
city induced by doxorubicin. Liposomal preparation of
drugs improves the cure rate by enhancing the half-life
of doxorubicin from minutes to an hour.152 At present,
there are no liposomal drug platforms available for the
direct treatment of CVDs in humans. Several studies
have conducted to exploit the possible benefits of liposo-
mal platforms for drug delivery. Clinical trials have carried
out where growth factors are delivered through a liposo-
mal and adenoviral vector for the treatment of myocardial
ischemia after angioplasty and stenting. They aim to pre-
vent restenosis after the angioplasty and stenting.153 Some
cases of liposomal delivery for gene transfer are found to
be feasible and well-tolerated, yet treatments fail to reduce
the frequency of restenosis. PEGylated liposomes encap-
sulated with therapeutic payloads of the AT1 receptor
enhanced the recovery of cardiac cells after the incidence
of a heart attack. In vivo studies revealed that this nano-
receptor formulation is adequate for specific targeting,
sustained release of the drug, increased accumulation in
the damaged site without harming the healthy cardiac
cells. The nano delivery system aided in the therapeutic
delivery of payloads to the damaged myocardium with
better therapeutic responses and excellent regeneration of
cardiac cells.154 There are Liposomal alendronate plat-
forms found as safer in early clinical trials for infusion at
the time of percutaneous coronary intervention.109
Liposomes have targeted the heart vasculature, which
contains several biomarkers. Vasculature targeting will
enable the treatment of the affected areas of the cardiovas-
cular system. C-Lipo, composed of a heart-targeting peptide,
CRPPR, is an arginine-rich sequence biomarker that shows
more than 300-fold selectivity for the endothelial cells of the
heart. Liposomal carriers of size 71 to 110 nm conjugated
with 18F-CRPPR are injected intravenously to the murine
model for targeting healthy cardiac vasculature. It could help
scientists to study the targeted delivery of peptides to heart
vasculature. Liposomal platforms with conjugate are found
in the heart within 100 seconds after the injection.155 CRPPR
peptide is also used to conjugate with surface altered lipo-
somes to target coronary endothelium in the myocardial
infarction and ischemia-reperfusion animal models.
Liposomal platforms are focused more on the injured tissue
of heart vasculature than healthy tissue suggesting a better
treatment rate.156 In a new study, a fluorescent-tagged
PEGylated liposomal system is used for active and passive
targeting to the infarcted heart. Passive targeting is carried
out due to the ischemic dysfunctional blood vessels present
in the left ventricle of the infarcted heart. Active targeting is
performed using the liposomal carrier with ligands for the
overexpressed angiotensin II type 1 receptor found in the
infarcted heart. This study also confirms the active or passive
targeting of liposomal platforms in the murine model of AMI
within a week compared to the non-targeted liposomes.157 A
study combining micellar and liposomal nanoformulations
for treating AMI suggests liposomes and micelles as pro-
angiogenic and cardioprotective drug delivery systems.158
Liposomes containing prednisone has used for the treatment
of patients with atherosclerotic plaques. Small interfering
RNA loaded onto polymer nanoparticles are delivered to
atherosclerotic lesions to reduce the monocyte trans endothe-
lial migration. The results have coincided with the reduced
inflammatory activity in the atherosclerotic plaque.159
There are cell-based targets present in the infarcted
site, which include macrophages. Phosphatidylserine (PS)
is a ligand expressed on apoptotic cells and elicits anti-
inflammation in the macrophages. Liposomal carriers with
PS attached to the surface can be employed for the selec-
tive targeting to macrophages. A series of events occur
after the engulfment of liposomes with PS such as the
production of high amounts of anti-inflammatory cyto-
kines, up-regulation of CD206 and downregulation of
TNF alpha and CD86.160 Modified liposomes carrying an
overall negative charge, nanogold, rhodamine and phos-
pholipase A2 (an inflammatory marker) target activated
macrophages in the atherosclerosis plaques. These lipo-
somes target more to the lipid-laden and metabolically
active areas of atheromas or atherosclerotic plaques.161
Saito and co-workers designed immunoliposome prepara-
tions to target carotid intimal hypertrophy in a rat model
induced by balloon injury. A potent Rho-kinase inhibitor,
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fasudil, and a ligand decorated on the surface of liposomes
had used to target LOX 1 on plaque lesions. LOX 1 is a
lectin-like LDL receptor 1. The ligand used is an anti-LOX
1 antibody conjugated to the liposome. Targeted liposomes
detected in the lesions decreased the expression of metal-
loproteinase-9 and intimal thickness.162 Cho et al worked
on a different approach to treat atherosclerosis. They
focused on solubilizing the bad cholesterol found in the
plaques. Liposomes loaded or conjugated with phosphati-
dylcholine are aimed to enrich the lesion with high-density
cholesterol. Typically, low-density cholesterol gathers at
the walls of arteries, and oxidized cholesterol is taken up
by foam cells. It resulted in the formation of atheroma.
High-density cholesterol limits the inflammatory process
by inhibiting the oxidation of LDL. Infusion of a liposo-
mal formulation containing drug significantly reduced the
plaque volume and cholesterol content on the walls. It
suggests liposomal drug combinations as a promising sub-
stitute for the treatment of plaque regression.163,164
PEGylated Liposomes functionalized with peptide
sequence of fibrinogen gamma-chain exhibited an efficient
delivery of recombinant plasminogen activator (rtPA) into
a rat model of inferior vena cava thrombosis for an
improved thrombolytic activity.75
Liposomal preparation containing prednisolone has used
to prevent in-stent restenosis in the rabbit model.
Prednisolone possesses a high affinity for chondroitin sulfate
proteoglycans present at the site of atheroma. It was able to
reduce the percentage of stenosis and side effects in the
atheroma model compared to the non-targeted liposomes.165
Liposomes loaded with nitric oxide and argon through freez-
ing under pressure technique are utilized for the therapy of
in-stent restenosis. In this method, high concentrations of
gases dissolved in solution had used, which get entrapped
in the liposomes during the freezing and thawing process.
Huang and coworkers synthesized positively charged echo-
genic liposomes conjugated to dimyristoyl phosphatidylcho-
line (anti-proliferative agent). Charged liposomal
formulations stimulate the relapse of lesions and reduction
of hyperplastic development of smooth muscle cells and
decrease the thickening of arterial walls in a balloon injured
atheroma model of rabbits.119 Liposomal platforms are also
proven as a successful therapeutic method of platelet target-
ing in CVDs. Liposomes with the modified surface are
always attractive in the treatment of CVDs due to their
improved and enhanced drug delivery to the injured cardio-
vascular tissues and surroundings.166 Liposomes loaded with
oligodextran surfactants and arginine-glycine-aspartic acid
can reduce the uptake of phagocytic cells of the reticuloen-
dothelial system. Surfactant attachment has similar activities
of cell glycocalyx and reduces the absorption of cells.
Platelets are targeted more due to the binding of the peptide
to the integrin present on the platelets. Thus, this study
reported the camouflage activity of liposomes to target plate-
lets, to diminish opsonization and the uptake of the
endothelial system.167 Likewise, Srinivasan and coworkers
determine the ability of liposomes to target platelets using
arginine-glycine-aspartic acid in a rat model of restenosis
with catheter induced carotid arterial injury. Results sug-
gested that liposomal platforms containing peptides may be
applied significantly to target platelets for the therapy of
CVDs.168
Dendrimers
Unique properties of dendrimers such as their tunable size,
multiple functional features, and outstanding biocompatibil-
ity, provide the opportunities to use polyamidoamine
(PAMAM) and polyethyleneimine as gene delivery agents.
These dendrimers interact with DNA/RNA and produce
dendriplexes through electrostatic interactions. Dendrimers
are promising nanocarriers with unique characteristics.
Dendrimers are flexible gene delivery vehicles to the injured
site as they carry a positive charge and smaller in size.169–171
Dendrimers have repeated branches with low polydispersity
and high molecular uniformity. Drug moieties have loaded
into the cavities and branch folding’s, which forms into the
shape of channels and cages. The applications of dendrimers
in targeted gene delivery to the injured cardiac tissues are
infinite. In one study, the authors reported the use of starburst
dendrimers for the transfer of genes (DNA or RNA) in
cardiac grafts.172 Polyethylene glycol altered polyamidoa-
mine was loaded with the recombinant plasmid, arginine-
glycine-aspartic acid peptide, and hirudine. This dendrimer
nanocomplex had used for the gene transfer and thrombosis
treatment. Acute myocardial infarction and stroke can be
prevented to an extent by treating the process of thrombosis.
Dendrimer-DNA nanocomplex efficiently delivered the
recombinant plasmid DNA at the site of thrombus formation
and suggested for thrombosis therapy. Gene delivery system
using dendrimers displayed little cytotoxicity in both in vitro
and in vivo models by enabling excellent delivery of recom-
binant hirudine plasmid DNA to treat thrombosis.88
Hyperbranched PAMAM is more advantageous than
PAMAM due to its ability to protect DNA from external
damages, less cytotoxicity, and high gene transfection effi-
ciency. A group of researchers synthesized hyper-branched
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dendrimers to transfer the hypoxia-controlled plasmid carrying
human vascular endothelial growth factor-165 into the skeletal
myoblasts. Transfer of the plasmid resulted in the expression
of the growth factor gene in the myoblast cell. Skeletal myo-
blasts manipulated with the gene of interest have transplanted
into the infarct myocardium for the repair of cardiac tissues in
the AMI animal model. Transplantation of transfected skeletal
myocardiumwith the gene of interest decreased the number of
apoptotic cells, enhanced the survival of grafted cells,
improved the blood vessel density, decreased the size of the
infarct, and enhanced the cardiac function.173,174 Simvastatin,
and nifedipine are two drugs used for the treatment of some
CVDs. Simvastatin inhibits the enzyme hydroxyl methyl glu-
taryl CoA reductase and lowers the blood cholesterol levels.
This drug is commonly used to treat hypercholesterolemia
coronary events but displays some side effects like insoluble
nature in water, less oral bioavailability, and irregular absorp-
tion. PAMAM dendrimer used to deliver the simvastatin has
enhanced bioavailability, solubility, and pharmacokinetic
properties and controlled release.175 Similarly, probucol cho-
lesterol-lowering drug shows side effects if applied directly for
the treatment. Thus, dendrimers can be loaded with the above
drug to improve its pharmacokinetic properties and biological
functions.176 Nifedipine is a calcium channel blocking drug
used to treat hypotensive and angina patients. G0–G3 dendri-
mers could be used to enhance the solubility and beneficial
effects for the treatment of CVDs. Amine and ester groups
present in the dendrimers significantly improve the
solubility and bioavailability of drugs for better treatment
efficiency.177,178
Polymeric and Magnetic Nanoparticles
Polymeric nanoparticles gained much interest in cardiovascu-
lar nanomedicine due to their modifying nature and probable
reabsorption in the body for maximum efficiency. Different
routes of delivery of these nanoparticles are oral, dermal,
mucosal, or transdermal, depending upon the site of action.52
The most commonly used polymers for the synthesis of bio-
degradable polymeric nanocarriers are poly lactic-co-glycolic
acid (PLGA), polyglycolic acid (PGA) and polylactic acid
(PLA). They are called biodegradable owing to their ease in
elimination from the human body as carbon dioxide andwater.
Among these polymers, PLGA has widely tested as drug
carriers for the treatment of CVDs.10 In a study, dextran-
coated nanoparticles used for the dual delivery of two model
drugs (poorly water-soluble drugs, SB431542 and
CHIR99021) to reprogram the fibroblasts into cardiomyo-
cytes. These drugs had encapsulated in the surface of the
AcDX nanoparticles functionalized with spermine, which
resulted in the pH triggered delivery into the fibroblasts.
Cellular reprogramming of myofibroblasts and fibroblasts in
the injured heart into healthy myocytes is always an attractive
therapeutic method to replace the lost cardiac cells.179 In
another work, polymeric nanoparticles fabricated with quer-
cetin using the method of electrohydrodynamic atomization
process for improved aqueous solubility and stability of the
drug. This resulted in the prevention of atherosclerosis pla-
ques. Encapsulation of this antioxidant agent on the PLGA
nanoparticles enhanced the pharmacological effect of drugs
due to the poor solubility and also reduced the production of
reactive oxygen species.180 Polymeric nanocarriers are used
for the targeted and controlled delivery of anti-proliferative
agents to treat damaged vasculature and regarded as a safe
approach to treat coronary artery disease also.181 It is clear that
reactive oxygen species (eg, Hydrogen peroxide) generated
due to the ischemia-reperfusion injury leads to vascular throm-
bosis and cardiac cell damage. Anticoagulant agents supplied
directly to the patients showed a slow drug release rate and a
short period of circulation in blood. Also, it causes adverse
side effects with the faster dissolution of clots in the thrombo-
occluded vessels. Hence, PLGA nanoparticles encapsulated
with antioxidant (glutathione) and anticoagulant agents
(heparin) exploited for the treatment of Ischemia/reperfusion
(I/R) injury. Controlled and targeted delivery of drugs
occurred within two hours indicating a potential platform to
treat vascular diseases.84
Recent developments in thefield of design and synthesis of
multifunctional nanostructures comprising magnetic or plas-
monic properties can be used as a powerful weapon to treat
CVDsby employingmagnetically assisted targeted drug deliv-
ery. Magnetic nanoparticles are being considered as safe MRI
contrast agents and drug delivery agents to treat cardiovascular
diseases. Drug loaded to magnetic nanoparticles can be easily
tracked and used for targeted delivery, which depends on the
contrasting agent employed. In this contest, iron oxide super-
paramagnetic nanoparticles are known as good nanocarriers to
treat AMI. Magnetic nanoparticles loaded with tissue plasmi-
nogen activator enabled the magnetic orientation of the plas-
minogen activator in an embolic rat model to enhance local
thrombolysis. It had found that the dose of drug bound to
magnetic nanoparticles required to dissolve the clot was 100
times less than that applied as free drug. It implies the broad
application of magnetic resonance tracking and delivery of
drugs to many of the occlusive vascular diseases.182
Magnetoliposomes are synthesized using magnetic nanoparti-
cles and liposomes and used for magnetic resonance imaging
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and targeted magnetic-based drug delivery in CVDs.
Magnetolipsomes are potential multifunctional drug delivery
systems. They are used to treat infarcted myocardium and for
the delivery of growth factors, biomolecules, and cytokines to
the degenerating cardiac cells.183 These nanoparticles effi-
ciently targeted angiotensin receptor 1, which has overex-
pressed in infarcted myocardium.184 Nanoparticles
encapsulated with p38 inhibitors minimized fibrotic region of
affected heart.185
Even though nanoparticles possess enormous potential
in cardiology, health risks, and safety associated with them
should be considered. The effect of nanoparticles on both
human health and the environment is to be assessed for
safety measures. Impacts of nanoparticles on health have
assessed by deposition and clearance of solid nanoparti-
cles, systemic translocation, biocompatibility, has implica-
tions on the intestinal tract and central nervous system and
bodily distribution. It is evident from studies that alteration
in the structural and physicochemical properties of nano-
particles with reduced material size may lead to toxic
effects (Figure 9). Hence, it is essential to bridge the gap
between the toxic impact of nanoparticles and health ben-
efits that have employed in CVDs.186
Future Perspectives and
Conclusions
It has evident that cardiovascular diseases and their asso-
ciated disorders are one of the principal reasons for global
morbidity and mortality. Even though some of the disor-
ders are manageable, coronary artery diseases remain as a
peril to biomedical researchers with rapid changes in the
human lifestyle. There are numerous cardio-protective
drugs available for the treatment and prevention of cardi-
ovascular diseases, and newer therapeutic methods are
gaining interest in the medical system. Among all treat-
ment modalities available, natural compounds, herbal
medications, and TCM found a place at the topmost stra-
tegies. These strategies and compounds are preferred over
synthetic drugs as the side effects associated with them are
very less. But these medications often failed to reach
clinical settings, as they have not supported by scientific
studies. Yet, researchers always demand new technologies
and innovations in the field of diagnosis and treatment of
CVDs more effectively and efficiently than older methods.
Conventional treatment modalities that target different
pathways such as lipid metabolism, blood volume, coagu-
lation cascade, and arterial constriction exhibits disadvan-
tages inefficient treatment of CVDs with side effects such
as thrombosis in stents, unusual activation of the immune
system and systemic toxicity. Thus, nano-drug delivery
systems have employed as an alternative vehicle for effi-
cient and controlled delivery of drugs into injured heart
tissue. Likewise, nanoparticles have tremendous applica-
tions in the diagnosis and imaging of CVDs as they allow
simple diagnosis of CVDs and real-time tracking during
therapy. Nanoimaging in CVD exploited various multi-
functional and multimodal imaging vehicle, which is not
possible with conventional imaging techniques.
Nanotechnology and nanomedicine offer individual
attention to the diagnostic and therapeutic fields of cardi-
ovascular diseases as theranostic agents. Nanosized parti-
cles act as nanodevices or nanocarriers for the successful
delivery of drugs to the injured site. Nanocarriers hold
promising potential for the efficient, targeted delivery of
drugs and genes that eliminate the problems associated
with the solubility, bioavailability, and other pharmacoki-
netic properties. The current review delivers an overview
of the different cardiovascular diseases and available ther-
apeutic methods along with recent advancements in the
field of treatment. It highlights and summarizes the rele-
vant efforts and improvements made towards the targeted
delivery of drugs to the cardiovascular tissues and their
biomarkers for the treatment. Besides, a lacuna has
observed in the field of nanomedicine for CVDs.
Although several cardiovascular nanoformulations are
tested in both in vitro and in vivo in clinical trials, their
Widely used nano-
drug delivery
systems
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nanoparticles
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Figure 9 Various types of nanoparticles widely used in the targeted delivery of
drugs to treat CVDs.
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clinical translation is still under development. It deals with
the problems of pharmaceutical scale-up, release efficiency,
substantial regulatory requirements exhibiting safety and
Good Manufacturing Practice (GMP). Furthermore, in vivo
and clinical trials are required to study the full effect of
nanoparticles in the body and on cardiac tissues. Future
designs and developments in the nanocarriers of CVDs
require studies with much rigor. Several natural products
derived from drugs and nanoformulations with cardioprotec-
tive activity are waiting for the research and clinical transla-
tions. The translational research of nanomedicine in CVDs
has many challenges that prevent its successful implantation
in clinics. These hurdles include institutional and industrial
interests, unavailability of proper infrastructure, and skills to
prepare patients for treatment, appropriate monitoring of
patient outcomes, registration of patients in clinical trials,
and country-specific compensation and affordability. Hence,
translational medicine in CVDs using nanoparticles should
be an integrative effort by bioengineers, pharmacists, che-
mists, biologists, and clinicians. Future research has targeted
to use peptides and antibodies to detect the markers of CVDs
and to develop selective nano delivery systems. Future nano-
cardio medicine is oriented to evaluate the clinical effects of
novel nanosystems to improve the quality of life.
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